(Q35144028)

6 August 2017

1 reference

title

Targeting cytokines in autoimmunity: new approaches, new promise (English)

1 reference

6 August 2017

Evangelos Andreakos

1

1 reference

PubMed ID

12783612

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

3

1 reference

6 August 2017

435-447

1 reference

Cytokines and anti-cytokine biologicals in autoimmunity: present and future

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Monoclonal antibodies in immune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and THP-1 monocytic cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Regulation of the interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Transcriptional mechanisms of chondrocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Activation of nuclear factor kappa B inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

A D-amino acid peptide inhibitor of NF-kappa B nuclear localization is efficacious in models of inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b-dependent signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.3.435

21 January 2018

Identifiers

DOI

10.1517/14712598.3.3.435

1 reference

6 August 2017

1 reference

PubMed ID

12783612